The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a common chronic skin inflammatory disorder characterized by recurrent eczema accompanied by an intractable itch that leads to an impaired quality of life. Extensive recent studies have shed light on the multifaceted pathogenesis of the disease. The complex interplay among skin barrier deficiency, immunological derangement, and pruritus contributes to the development, progression, and chronicity of the disease. Abnormalities in filaggrin, other stratum corneum constituents, and tight junctions induce and/or promote skin inflammation. This inflammation, in turn, can further deteriorate the barrier function by downregulating a myriad of essential barrier-maintaining molecules. Pruritus in AD, which may be due to hyperinnervation of the epidermis, increases pruritogens, and central sensitization compromises the skin integrity and promotes inflammation. There are unmet needs in the treatment of AD. Based on the detailed evidence available to date, certain disease mechanisms can be chosen as treatment targets. Numerous clinical trials of biological agents are currently being conducted and are expected to provide treatments for patients suffering from AD in the future. This review summarizes the etiopathogenesis of the disease and provides a rationale for choosing the novel targeted therapy that will be available in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Atopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,055
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978 · cited 1×
“FLG is known to be decreased in the epidermis of AD patients [34], and null mutation in FLG is the strongest risk factor for AD [35].”
BackgroundTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“Moreover, a recent phase III study has confirmed the findings in a larger number of patients [184].”
ResultEndogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Kong, H. H., Oh, J., Deming, C., Conlan, S., Grice, E. A., Beatson, M. A., Nomicos, E., Polley, E. C., Komarow, H. D., Program, N. C. S., et al. (2012) · Genome Research · doi:10.1101/gr.131029.111 · Cited by 1,808 · cited 1×
“aureus colonization and/or infections with a loss of microbial diversity during flares [121].”
BackgroundBieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Cited by
Pathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Self-citationType 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C.-Y., Liu, Z., Gontijo Lima, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206714 · Cited by 345
Metadata
- Authors
- Rerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K.
- Affiliations
- Chulalongkorn University (TH)
- Kyoto University (JP)
- Agency for Science, Technology and Research (SG)
- Corresponding author
- Otsuka, Atsushi
- Kabashima, Kenji
- Venue
- Inflammation and Regeneration
- Published
- 2017-06-05
- Volume
- 37
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1346-8022 (ISSN-L)
- 1880-8190
- PMC
- PMC5725646
- OpenAlex
- W2623738179
- Cited by
- 187
- References
- 215
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 29 · 2023: 18 · 2022: 19 · 2021: 30 · 2020: 21 · 2019: 22 · 2018: 12
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Inflammation and Regeneration (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministries of Education, Culture, Sports, Science and Technology
- the Japan Agency for Medical Research and Development (AMED)
- Ministry of Health, Labour and Welfare Sciences
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, etiopathogenesis, skin barrier dysfunction, filaggrin, stratum corneum, tight junctions, pruritus, central sensitization, pruritogens, skin inflammation, biologic therapy, targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. https://app.cochat.ai/papers/10.1186/s41232-017-0044-7
- The paper
- Rerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K. (2017). The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflammation and Regeneration. https://doi.org/10.1186/s41232-017-0044-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.